For pharma and biotech companies, tech solution providers, startups, and early-stage companies.
COVID-19 has accelerated the need for digital health technology across the healthcare ecosystem, with important implications for pharma and biotech, medical device and tech solution providers, and startups. From telehealth services to decentralized virtual clinical trials, and emerging technologies such as artificial intelligence and machine learning, companies must have an informed strategy and an innovation lifecycle that can keep pace with a shifting environment and scale.
Actionable insights at every point along the Innovation Lifecycle
The CIDH Digital HealthCare Advisory Services combines clinical excellence, a tradition of innovation, and the collective wisdom of leading clinicians, academicians, and researchers to help create standard-setting digital health strategies and improve patient care.
Providing guidance and support throughout the innovation lifecycle with respect to:
Global Biopharma Company Developing Chronic Disease Management Platform
A global biopharmaceutical company with a minimum viable product partnered with CIDH to create and clinically validate patient-centric digital health solutions and establish a new standard of care for chronic illness management outside of a clinical setting.
Working collaboratively with the company, we aligned on three- to five-year product and research roadmaps, and engaged clinical, technical, and operational experts to support product iteration, testing, and validation, as well as subject matter expertise in data and analytics, remote patient monitoring, value-based care, and chronic disease management in three clinical care areas. Our guidance on Information Security requirements and Electronic Health Records (EHR) integration processes resulted in an accelerated EHR integration. CIDH also worked with the company on their Evidence Generation approach and study design, aiming towards clinical validation and publication.
Start-up Developing Digital Therapeutic for Chronic Musculoskeletal Pain
A start-up company focused on pioneering virtual musculoskeletal (MSK) pain programs and pain neuroscience education for employers, sought a range of advisory services to create commercial and investor value and improve patient care via cutting edge technology.
Leading clinicians from Mass General’s Department of Anesthesia, Critical Care and Pain Medicine provided guidance on business strategy and the development of rapidly expanding protocols to address chronic MSK pain, as well as pain management, and a pain specialist from MGH joined the company and served as the company’s interim Chief Medical Officer. The company was introduced to other innovation groups and investment funds at Mass General Brigham and is now on a path to gain credibility among payors and clinicians in order to compete in the market.
Early-stage Company Focused on Maternal Health for Women of Color
Engaged as a dedicated advisor for an early-stage maternal health company focused on building a digital solution to cultivate a community of mothers of color and provide guidance/support during their pregnancy journey. The company was looking for advice on market entry strategy as well as access to clinicians who care for this patient population. In addition, the company was looking for advice on developing and testing digital health applications at a large Academic Medical Center (AMC). This early-stage company received meaningful feedback from our subject matter experts to inform key business decisions, including the product roadmap, funding and financing decisions for a sustainable business model, and insights into Mass General’s commitment to address inequities in access to care. In addition, the company further refined their investor pitch for upcoming presentations and discussions for funding opportunities. We are excited that this early-stage company has generated positive media coverage, including recognition as a ‘change-maker’ in a major trade publication.